Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Salarius Pharmaceuticals ( (SLRX) ).
On December 31, 2025, Salarius Pharmaceuticals reconvened its 2025 Annual Meeting of Stockholders, originally held on December 19, 2025, with 39.7% of the 1,051,782 outstanding common shares represented, constituting a quorum. At the meeting, shareholders re-elected two Class I directors to serve until the 2028 annual meeting, approved on a non-binding basis the compensation of the company’s named executive officers and ratified Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, collectively signaling continued shareholder support for the company’s current leadership, governance practices and financial oversight arrangements.
The most recent analyst rating on (SLRX) stock is a Hold with a $0.61 price target. To see the full list of analyst forecasts on Salarius Pharmaceuticals stock, see the SLRX Stock Forecast page.
Spark’s Take on SLRX Stock
According to Spark, TipRanks’ AI Analyst, SLRX is a Neutral.
The score is held down primarily by weak financial performance (no revenue, ongoing losses, and continued cash burn) and very bearish technicals (price far below major moving averages with negative MACD). Corporate events provide some offset via financing, a merger, and Nasdaq compliance progress, but valuation metrics offer limited support given negative earnings and no dividend data.
To see Spark’s full report on SLRX stock, click here.
More about Salarius Pharmaceuticals
Salarius Pharmaceuticals, Inc. is a biopharmaceutical company operating in the life sciences sector. While this release does not detail its specific therapeutic focus or products, the company functions as a publicly traded corporation with a typical governance structure that includes a board of directors, executive officers and an independent registered public accounting firm overseeing its financial reporting.
Average Trading Volume: 1,842,719
Technical Sentiment Signal: Sell
Current Market Cap: $4.14M
For a thorough assessment of SLRX stock, go to TipRanks’ Stock Analysis page.